The approval of cytisine, a plant-based drug used for smoking cessation in several countries, is delayed in the U.S. due to the FDA’s request for additional safety data. Experts warn this could prevent thousands of Americans from quitting smoking.
Cytisine has been available in countries like Canada and the U.K. for years and is known to be more effective than nicotine patches and gum. It also causes fewer side effects than varenicline, a commonly used smoking cessation drug.
The FDA’s request has delayed cytisine’s potential U.S. approval by at least a year.
According to a recent study, if cytisine were available in the U.S., it could help around 71,000 people quit smoking in just one year, potentially adding over 500,000 life-years by reducing smoking-related deaths.
Point phone camera here
The delay could reduce these gains by 10,000 life-years annually.
Cytisine works by targeting nicotine receptors in the brain, reducing cravings and the satisfaction from smoking. It’s been shown to be more effective than current nicotine replacement therapies and has milder withdrawal symptoms than varenicline.
Research from the University of Oxford supports cytisine’s potential to help smokers quit, and ongoing clinical trials in the U.S. have shown positive early results. Despite the promising data, the FDA’s demand for further safety information has pushed back the drug’s approval.
Public health experts emphasize the need for timely approval, given the high relapse rates among smokers and the limitations of existing treatments. Delays, they argue, could result in significant public health setbacks.
[karah rucker]
A DRUG THAT HAS HELPED THOUSANDS QUIT SMOKING WORLDWIDE IS STILL UNAVAILABLE IN THE U-S.
CYTISINE, A PLANT-BASED SMOKING CESSATION TREATMENT USED IN COUNTRIES LIKE CANADA AND THE UK, IS AWAITING FDA APPROVAL AFTER THE AGENCY REQUESTED MORE SAFETY DATA. EXPERTS SAY THE DELAY COULD PREVENT THOUSANDS OF AMERICANS FROM QUITTING TOBACCO.
CYTISINE HAS BEEN FOUND TO BE MORE EFFECTIVE THAN NICOTINE PATCHES AND GUM AND CAUSES FEWER SIDE EFFECTS THAN OTHER DRUGS ON THE MARKET.
APPROVED IN CANADA IN 2017 AND THE UK IN 2024, CYTISINE WORKS BY BINDING TO NICOTINE RECEPTORS IN THE BRAIN, REDUCING CRAVINGS AND THE SATISFACTION FROM SMOKING. RESEARCHERS ESTIMATE THAT IF AVAILABLE IN THE U.S., CYTISINE COULD HELP OVER 70,000 AMERICANS QUIT SMOKING EACH YEAR.
ACHIEVE LIFE SCIENCES, A BIOTECH COMPANY, HAS BEEN CONDUCTING CLINICAL TRIALS IN THE U.S. TO GAIN FDA APPROVAL. SO FAR THOSE TRIALS HAVE SHOWN POSITIVE OUTCOMES, WITH ABOUT 20% OF PARTICIPANTS STAYING SMOKE-FREE FOR SIX MONTHS COMPARED TO 5% USING A PLACEBO.
HOWEVER, THE FDA’S REQUEST FOR MORE SAFETY DATA HAS PUSHED BACK POTENTIAL APPROVAL BY AT LEAST A YEAR.
EXPERTS FROM MASSACHUSETTS GENERAL HOSPITAL SAY EVERY YEAR THIS TREATMENT IS DELAYED – IT COSTS 10-THOUSAND COLLECTIVE LIFE-YEARS OF SMOKERS.
RESEARCHERS AND TOBACCO EXPERTS ARE CONTINUING CLINICAL TRIALS, HOPING TO BRING THIS AFFORDABLE AND EFFECTIVE TREATMENT TO THE U.S. MARKET SOON.
FOR MORE OF OUR UNBIASED — STRAIGHT FACTS REPORTING — DOWNLOAD THE STRAIGHT ARROW NEWS APP OR VISIT US AT SAN – DOT – COM.
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.
